scholarly journals Preoperative 2D-echocardiographic assessment of pulmonary arterial pressure in subgroups of liver transplantation recipients

2021 ◽  
Vol 16 (4) ◽  
pp. 344-352
Author(s):  
Jungchan Park ◽  
Myung Soo Park ◽  
Ji-Hye Kwon ◽  
Ah Ran Oh ◽  
Seung-Hwa Lee ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Arterial Pressure ◽  
Pulmonary Arterial Pressure ◽  
Systolic Pressure ◽  
Heart Catheterization ◽  
Predictive Values ◽  
Ventricular Systolic Pressure ◽  
2D Echocardiography ◽  
Echocardiographic Assessment ◽  
Pulmonary Arterial

Background: The clinical efficacy of preoperative 2D-echocardiographic assessment of pulmonary arterial pressure (PAP) has not been evaluated fully in liver transplantation (LT) recipients.Methods: From October 2010 to February 2017, a total of 344 LT recipients who underwent preoperative 2D-echocardiography and intraoperative right heart catheterization (RHC) was enrolled and stratified according to etiology, disease progression, and clinical setting. The correlation of right ventricular systolic pressure (RVSP) on preoperative 2D-echocardiography with mean and systolic PAP on intraoperative RHC was evaluated, and the predictive value of RVSP > 50 mmHg to identify mean PAP > 35 mmHg was estimated.Results: In the overall population, significant but weak correlations were observed (R = 0.27; P < 0.001 for systolic PAP, R = 0.24; P < 0.001 for mean PAP). The positive and negative predictive values of RVSP > 50 mmHg identifying mean PAP > 35 mmHg were 37.5% and 49.9%, respectively. In the subgroup analyses, correlations were not significant in recipients of deceased donor type LT (R = 0.129; P = 0.224 for systolic PAP, R = 0.163; P = 0.126 for mean PAP) or in recipients with poorly controlled ascites (R = 0.215; P = 0.072 for systolic PAP, R = 0.21; P = 0.079 for mean PAP). Conclusion: In LT recipients, the correlation between RVSP on preoperative 2D-echocardiography and PAP on intraoperative RHC was weak; thus, preoperative 2D-echocardiography might not be the optimal tool for predicting intraoperative PAP. In LT candidates at risk of pulmonary hypertension, RHC should be considered.

Liver Transplantation for Patients with Portopulmonary Hypertension: a Case Report and Review of the Literature

2015 ◽  
Vol 25 (2) ◽  
pp. 19-23
Author(s):  
Andrius Macas ◽  
Limas Kupčinskas ◽  
Giedrius Barauskas ◽  
Darius Trepenaitis ◽  
Juozas Kupčinskas ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Case Report ◽  
Arterial Pressure ◽  
Pulmonary Arterial Pressure ◽  
Heart Function ◽  
Perioperative Complications ◽  
Heart Catheterization ◽  
Portopulmonary Hypertension ◽  
Vasodilator Drugs ◽  
Pulmonary Arterial

Portopulmonary hypertension is one of the complications for people with end stage chronic liver disease. This condition occurs to 5-8% of people, who need liver transplantation, and it causes a higher risk of perioperative complications or these patients are even banned from this procedure. Therefore, it is very important to diagnose this pathology in time using right heart catheterization and provocative volume and dobutamine samples for evaluation of the right ventricle function. Fortunately, adequate medical treatment with its most important part – vasodilator drugs - cures portopulmonary hypertension or lowers the perioperative risk caused by this condition. This case report presents a 50-year-old male hospitalized for liver transplantation. The patient has cirrhosis of the liver caused by hepatitis C, liver failure and portopulmonary hypertension. He has been taking vasodilator drugs for almost 8 months in order to prepare for a surgical treatment and when the operation’s day came, all tests needed including echocardiography shown that the transplantation could be performed. During the operation patient’s heart function was monitored with transesophageal echocardiography. Even though the mean pulmonary arterial pressure was marginal, the operation was successful and the patient could be extubated right after the procedure. Systolic pulmonary arterial pressure of the recipient dropped from 70 mmHg to 60.

PULMONARY VASCULAR ADJUSTMENTS IN THE NEONATAL PERIOD

PEDIATRICS ◽  
1961 ◽  
Vol 28 (1) ◽  
pp. 28-34 ◽  
Author(s):  
Abraham M. Rudolph ◽  
Peter A. M. Auld ◽  
Richard J. Golinko ◽  
Milton H. Paul
Keyword(s):  
Arterial Pressure ◽  
Pulmonary Circulation ◽  
Neonatal Period ◽  
Pulmonary Arterial Pressure ◽  
Systolic Pressure ◽  
Indwelling Catheters ◽  
Pulmonary Vessels ◽  
Pulmonary Arterial ◽  
Unanesthetized Animals ◽  
Young Puppy

Pulmonary arterial or right ventricular pressures were measured repeatedly in 18 puppies and 2 goats, from 1 to 36 days of age; these pressures were measured with the use of indwelling catheters in unanesthetized animals. In puppies the systolic pressure in the pulmonary circulation decreased rapidly to near adult levels in 5 to 10 days after birth, and then more slowly to adult levels by 5 to 6 weeks of age. In goats the pressures decreased more slowly, reaching near adult levels in about 12 to 14 days. Acetylcholine produced a decrease in pulmonary arterial pressure in the puppy in the first 5 days of life, but an increase in pulmonary pressure after that time in the resting animal. In the hypoxic puppy, a reduction in pulmonary arterial pressure was induced by acetylcholine. These findings suggest that the pulmonary vessels in the young puppy are actively constricted but that relaxation occurs after the first few days of life.

THE NATURAL HISTORY OF PULMONARY HYPERTENSION IN CHILDREN WITH VENTRICULAR SEPTAL DEFECTS ASSESSED BY SERIAL RIGHT-HEART CATHETERIZATION

PEDIATRICS ◽  
1961 ◽  
Vol 27 (4) ◽  
pp. 621-626
Author(s):  
Robert E. Stanton ◽  
Donald C. Fyler
Keyword(s):  
Natural History ◽  
Arterial Pressure ◽  
Pulmonary Arterial Pressure ◽  
Clinical Status ◽  
Right Heart Catheterization ◽  
Heart Catheterization ◽  
Ventricular Septal Defects ◽  
Septal Defects ◽  
History Of ◽  
Pulmonary Arterial

The natural history of the pulmonary arterial pressure in 23 children with isolated ventricular septal defects has been evaluated by serial night heart catheterization. In none of the 23 patients was there a significant increase in pulmonary arterial pressure. Eight patients showed a significant decrease. The direction of shunts did not change between procedures, and the clinical status was stable. Our experience correlated well with the majority of institutions. It would appear that the natural course of pulmonary arterial pressure in ventricular septal defect is not commonly one of progressive rise.

scholarly journals Investigating Cardiac MRI Based Right Ventricular Contractility as a Novel Non-Invasive Metric of Pulmonary Arterial Pressure

2014 ◽  
Vol 8s1 ◽  
pp. CMC.S15711 ◽  
Author(s):  
Prahlad G. Menon ◽  
Srilakshmi M. Adhypak ◽  
Ronald B. Williams ◽  
Mark Doyle ◽  
Robert W. W. Biederman
Keyword(s):  
Systolic Pressure ◽  
Right Heart Catheterization ◽  
Three Dimensions ◽  
Heart Catheterization ◽  
Ventricular Contractility ◽  
Shape Variation ◽  
Predictive Values ◽  
Non Invasive ◽  
Pulmonary Arterial ◽  
Rv Function

Background We test the hypothesis that cardiac magnetic resonance (CMR) imaging-based indices of four-dimensional (4D) (three dimensions (3D) + time) right ventricle (RV) function have predictive values in ascertaining invasive pulmonary arterial systolic pressure (PASP) measurements from right heart catheterization (RHC) in patients with pulmonary arterial hypertension (PAH). Methods We studied five patients with idiopathic PAH and two age and sex-matched controls for RV function using a novel contractility index (CI) for amplitude and phase to peak contraction established from analysis of regional shape variation in the RV endocardium over 20 cardiac phases, segmented from CMR images in multiple orientations. Results The amplitude of RV contractility correlated inversely with RV ejection fraction (RVEF; R2 = 0.64, P = 0.03) and PASP ( R2 = 0.71, P = 0.02). Phase of peak RV contractility also correlated inversely to RVEF ( R2 = 0.499, P = 0.12) and PASP ( R2 = 0.66, P = 0.04). Conclusions RV contractility analyzed from CMR offers promising non-invasive metrics for classification of PAH, which are congruent with invasive pressure measurements.

scholarly journals Right ventricle performances with echocardiography and 99mTc myocardial perfusion imaging in pulmonary arterial hypertension patients

2018 ◽  
Vol 243 (9) ◽  
pp. 754-761
Author(s):  
Jie Liu ◽  
Lei Fei ◽  
Guang-Qing Huang ◽  
Xiao-Ke Shang ◽  
Mei Liu ◽  
...  
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Myocardial Perfusion ◽  
Arterial Pressure ◽  
Right Ventricle ◽  
Arterial Hypertension ◽  
Pulmonary Arterial Pressure ◽  
Right Heart Catheterization ◽  
Heart Catheterization ◽  
Mean Pulmonary Arterial Pressure ◽  
Pulmonary Arterial

Right heart catheterization is commonly used to measure right ventricle hemodynamic parameters and is the gold standard for pulmonary arterial hypertension diagnosis; however, it is not suitable for patients’ long-term follow-up. Non-invasive echocardiography and nuclear medicine have been applied to measure right ventricle anatomy and function, but the guidelines for the usefulness of clinical parameters remain to be established. The goal of this study is to identify reliable clinical parameters of right ventricle function in pulmonary arterial hypertension patients and analyze the relationship of these clinical parameters with the disease severity of pulmonary arterial hypertension. In this study, 23 normal subjects and 23 pulmonary arterial hypertension patients were recruited from January 2015 to March 2016. Pulmonary arterial hypertension patients were classified into moderate and severe pulmonary arterial hypertension groups according to their mean pulmonary arterial pressure levels. All the subjects were subjected to physical examination, chest X-ray, 12-lead electrocardiogram, right heart catheterization, two-dimensional echocardiography, and technetium 99m (99mTc) myocardial perfusion imaging. Compared to normal subjects, the right heart catheterization indexes including right ventricle systolic pressure, right ventricle end diastolic pressure, pulmonary artery systolic pressure, pulmonary artery diastolic pressure, pulmonary vascular resistance, and right ventricle end systolic pressure increased in pulmonary arterial hypertension patients and were correlated with mean pulmonary arterial pressure levels. Echocardiography parameters, including tricuspid regurgitation peak velocity, tricuspid regurgitation pressure gradient, tricuspid annular plane systolic excursion and fractional area, right ventricle-myocardial performance index, were significantly associated with the mean pulmonary arterial pressure levels in pulmonary arterial hypertension patients. Furthermore, myocardial perfusion imaging was not observed in the normal subjects but in pulmonary arterial hypertension patients, especially severe pulmonary arterial hypertension subgroup, and showed potential diagnostic properties for pulmonary arterial hypertension. In conclusion, mean pulmonary arterial pressure levels are correlated with several right heart catheterization and echocardiography markers in pulmonary arterial hypertension patients; echocardiography and 99mTc myocardial perfusion can be used to evaluate right ventricle performance in pulmonary arterial hypertension patients. Impact statement In this study, we analyzed the clinical parameters for evaluating RV function, including right ventricle catheterization (RHC), echocardiography, and technetium 99m (99mTc) myocardial perfusion imaging (MPI) in normal Asian subjects and PAH patients ( n = 23 for each group). Our results demonstrated that six RHC indexes, four echocardiography indexes and MPI index were significantly altered in PAH patients and correlated with the levels of mean pulmonary arterial pressure. Importantly, we evaluated the diagnostic performance of MPI and found that MPI has a strong diagnostic accuracy in PAH patients. The findings from this study will be of interest to clinical investigators who make diagnosis and therapeutic strategies for PAH patients.

scholarly journals Impact of the updated hemodynamic definitions on diagnosis rates of pulmonary hypertension

2020 ◽  
Vol 10 (3) ◽  
pp. 204589402093129
Author(s):  
Seda Tanyeri ◽  
Ozgur Y. Akbal ◽  
Berhan Keskin ◽  
Aykun Hakgor ◽  
Ali Karagoz ◽  
...  
Keyword(s):  
Pulmonary Hypertension ◽  
Arterial Pressure ◽  
European Society ◽  
Pulmonary Arterial Pressure ◽  
Heart Catheterization ◽  
Mean Pulmonary Arterial Pressure ◽  
Pressure Threshold ◽  
Normal Mean ◽  
Pulmonary Arterial ◽  
European Society Of Cardiology

We evaluated whether updated pulmonary hypertension definitive criteria proposed in sixth World Symposium on Pulmonary Hypertension had an impact on diagnosis of overall pulmonary hypertension and pre-capillary and combined pre- and post-capillary phenotypes as compared to those in European Society of Cardiology/European Respiratory Society 2015 pulmonary hypertension Guidelines. Study group comprised the retrospectively evaluated 1300 patients (age 53.1 ± 18.8 years, female 807, 62.1%) who underwent right heart catheterization with different indications between 2006 and 2018. Mean pulmonary arterial pressure ≥25 mmHg (European Society of Cardiology) and PAMP (mean pulmonary arterial pressure) >20 mmHg (World Symposium on Pulmonary Hypertension) right heart catheterization definitions criteria were used, respectively. For pre-capillary pulmonary hypertension, pulmonary artery wedge pressure ≤15 mmHg and pulmonary vascular resistance ≥3 Wood units criteria were included in the both definitions. Normal mean pulmonary arterial pressure (<21 mmHg), borderline mean pulmonary arterial pressure elevation (21–24 mmHg), and overt pulmonary hypertension (≥25 mmHg) were documented in 21.1, 9.8, and 69.1% of the patients, respectively. The pre-capillary and combined pre- and post-capillary pulmonary hypertension were noted in 2.9 and 1.1%, 8.7 and 2.5%, and 34.6 and 36.6% of the patients with normal mean pulmonary arterial pressure, borderline, and overt pulmonary hypertension subgroups, respectively. The World Symposium on Pulmonary Hypertension versus European Society of Cardiology/European Respiratory Society definitions resulted in a net 9.8% increase in the diagnosis of overall pulmonary hypertension whereas increases in the pre-capillary pulmonary hypertension and combined pre- and post-capillary pulmonary hypertension diagnosis were only 0.8 and 0.3%, respectively. The re-definition of mean pulmonary arterial pressure threshold seems to increase the frequency of the overall pulmonary hypertension diagnosis. However, this increase was mainly originated from those in post-capillary pulmonary hypertension subgroup whereas its impact on pre-capillary and combined pre- and post-capillary pulmonary hypertension was negligible. Moreover, criteria of pre-capillary pulmonary vascular disease and combined pre- and post-capillary phenotypes were still detectable even in the presence of normal mean pulmonary arterial pressure. The obligatory criteria of pulmonary vascular resistance ≥3 Wood units seems to keep specificity for discrimination between pre-capillary versus post-C pulmonary hypertension after lowering the definitive mean pulmonary arterial pressure threshold to 20 mmHg.

Echocardiographic assessment of pulmonary arterial pressure in the follow-up of patients with pulmonary embolism

2011 ◽  
Vol 127 (4) ◽  
pp. 303-308 ◽  
Author(s):  
Remedios Otero ◽  
Mikel Oribe ◽  
Aitor Ballaz ◽  
David Jimenez ◽  
Fernando Uresandi ◽  
...  
Keyword(s):  
Pulmonary Embolism ◽  
Arterial Pressure ◽  
Pulmonary Arterial Pressure ◽  
Echocardiographic Assessment ◽  
Pulmonary Arterial

scholarly journals Early treatment with ambrisentan of mildly elevated mean pulmonary arterial pressure associated with systemic sclerosis: a randomized, controlled, double-blind, parallel group study (EDITA study)

2019 ◽  
Vol 21 (1) ◽  
Author(s):  
Zixuan Pan ◽  
Alberto M. Marra ◽  
Nicola Benjamin ◽  
Christina A. Eichstaedt ◽  
Norbert Blank ◽  
...  
Keyword(s):  
Systemic Sclerosis ◽  
Arterial Pressure ◽  
Primary Endpoint ◽  
Pulmonary Arterial Pressure ◽  
Controlled Study ◽  
Heart Catheterization ◽  
Double Blind ◽  
Mean Pulmonary Arterial Pressure ◽  
Parallel Group ◽  
Pulmonary Arterial

Abstract Objective The objective of this randomized, placebo-controlled, double-blind, parallel group, trial was to assess the effect of ambrisentan on mean pulmonary arterial pressure (mPAP) in patients with systemic sclerosis (SSc) and mildly elevated pulmonary hypertension (PH). Methods Thirty-eight SSc patients with mildly elevated mPAP at rest between 21 and 24 mmHg and/or > 30 mmHg during low-dose exercise were randomly assigned to treatment with either ambrisentan 5–10 mg/day or placebo. Right heart catheterization and further clinical parameters were assessed at baseline and after 6 months. The primary endpoint was the difference of mPAP change at rest between groups. Results After 6 months, the two groups did not differ in the primary endpoint (ambrisentan mPAP − 1 ± 6.4 mmHg vs. placebo − 0.73 ± 3.59 mmHg at rest, p = 0.884). However, three patients from the placebo group but none of the ambrisentan group progressed to SSc-associated pulmonary arterial hypertension. Furthermore, ambrisentan treatment showed significant improvements in the secondary endpoints cardiac index (CI) and pulmonary vascular resistance (PVR) at rest (CI 0.36 ± 0.66 l/min/m2 vs. − 0.31 ± 0.71 l/min/m2, p = 0.010; PVR − 0.70 ± 0.78 WU vs. 0.01 ± 0.71 WU, p = 0.012) and during exercise (CI 0.7 ± 0.81 l/min/m2 vs. − 0.45 ± 1.36 l/min/m2, p = 0.015; PVR − 0.84 ± 0.48 WU vs. − 0.0032 ± 0.34 WU, p < 0.0001). Conclusion This is the first randomized, double-blind, placebo-controlled study testing the effect of ambrisentan in patients with mildly elevated mPAP and/or exercise PH. The primary endpoint change in mPAP did only tendentially improve in the ambrisentan group, but the significant improvement of other hemodynamic parameters points to a possible benefit of ambrisentan and will be helpful to design future trials. Trial registration www.ClinicalTrials.gov, unique identifier NCT: NCT02290613, registered 14th of November 2014.

scholarly journals EXPRESS: Carfilzomib-associated Pulmonary Arterial Hypertension in Multiple Myeloma

2021 ◽  
pp. 204589402110493
Author(s):  
Jenny Yang ◽  
Taylor Buckstaff ◽  
Anna Narezkina ◽  
Timothy Fernandes
Keyword(s):  
Multiple Myeloma ◽  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Right Ventricular ◽  
Systolic Pressure ◽  
New Drugs ◽  
Heart Catheterization ◽  
Drug Induced ◽  
Ventricular Systolic Pressure ◽  
Pulmonary Arterial

Drug-induced pulmonary arterial hypertension (PAH) is constantly evolving as new drugs are developed. Carfilzomib is a recently approved therapy for relapsed and refractory multiple myeloma. While it has been associated with cardiovascular adverse events, such as ischemic heart disease and heart failure, PAH has not been a well-described side effect. We present two patients who developed PAH associated with initiation of carfilzomib. They both initially presented with severe dyspnea, had elevated right ventricular systolic pressure on transthoracic echocardiography and ultimately underwent right heart catheterization. With discontinuation of carfilzomib, both patients had improvement in hemodynamics. However, one patient required initiation of PAH-targeted therapies and has had worsening right ventricular function again despite permanent discontinuation of carfilzomib. It is important to recognize the association between carfilzomib and PAH. Echocardiography can be an important initial screening tool. PAH from carfilzomib therapy may be reversible, especially if diagnosed early, however extended follow up is essential.

Sign in / Sign up

Export Citation Format

Share Document